Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
about
The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention"Challenging and complex decisions in the management of the BRCA mutation carrierSerous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review.The disparate origins of ovarian cancers: pathogenesis and prevention strategies.Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the EvidenceConditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association ConsortiumDistinct expression pattern and post-transcriptional regulation of cell cycle genes in the glandular epithelia of avian ovarian carcinomasProteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinomaFactors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.Ovarian cancer survival by tumor dominance, a surrogate for site of origin.Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy.Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer.Technical challenges and limitations of current mouse models of ovarian cancer.Mucinous borderline tumor involving fallopian tube: case report and review of the literatureMicroscopic lesions of fallopian tubes in endometrioid carcinoma of the endometrium: How effective are the macroscopic tubal sampling techniques?Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.Ovarian cancer risk factors by tumor dominance, a surrogate for cell of originSerial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursorsTargeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Pathogenesis and heterogeneity of ovarian cancer.Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.Early preinvasive lesions in ovarian cancer.Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue.Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol.
P2860
Q27025315-C78489B0-1CD4-4412-8525-0C956056A28EQ27026559-088C8E61-2FCE-407D-A535-D2DF7766D811Q30235845-FD8645B2-54B5-4421-AB5B-45453B3DEA3BQ30240709-EC11D4AC-2414-4D96-BFF2-AD32EAD8DF32Q30250107-88F6B2A9-0E9A-4FEE-AE52-2236DCED6CE6Q33521701-24005A28-B0EE-4562-900B-D7C0C5E2BD3FQ34033619-9B36A24D-760A-41AC-91B0-FCE43D055593Q34390396-8002E605-E968-45BA-8F28-D91991F1CBB3Q34453723-FA181EFC-AFCC-4CD1-8BFF-23335DCB65DAQ34511086-71E9CBD2-D376-4CB1-AB52-974B2BC6EDA3Q34669870-E047B9B9-8E85-4A19-8A32-D64297279BBDQ34990489-CBF5CBCC-86F8-42D5-9533-60B5AE39D181Q35519808-B075C063-A5B3-41A1-B7D1-40FCA2C6E910Q35690548-5FB88E01-F11D-49C7-B356-EFE578F4572EQ35749439-6D4ACF86-C02F-4070-9914-2DD23F057574Q36032691-2ABC587B-45E8-43DE-ACC6-B3EC5EDCE53DQ36173170-1B35EC53-CA8A-4589-B00B-2024F1C66066Q36219581-CEE99D67-A2CC-4C5C-854C-CA16CCF5B88BQ36464585-ABB87892-1350-480D-981C-588F5CEADB5EQ36510070-B1771489-BC4F-4AB8-A591-11AD89FEB32FQ36800356-C04086B5-EB02-4EA2-98BB-4CAEC3F235DAQ36817471-653B0E49-A9B4-4BA3-A250-F18CE0C69ED4Q36916354-9742F587-35D2-48D1-8AD5-F0921D0B328CQ36948873-F4EF036B-FCA0-48AA-878F-DDA7BC79D0DCQ37029695-42322939-5479-4018-8384-8DB7708580B9Q37225222-41E1E8F7-E71C-4070-89E7-2DB5C944DE25Q37244240-E63405C3-9E45-4DE1-B91F-C6A72A8AF94BQ37485865-6FD9549C-BD1B-4F12-86F5-686277D71DE9Q37546692-3E04C8A5-6E8F-46CF-901C-7FE880F99B00Q37553978-3BF7E625-90FC-40F5-8CC7-A7338CD55178Q37626525-BE674526-2D2F-4348-89FC-63230CF614ADQ37719090-E722B6BA-77A0-4A5E-A02F-184A4923EEA0Q38067435-0D489CBA-29B4-47E2-8E23-63F0AA21B2BCQ38340008-2693BFAB-1339-4C88-9027-32206C11FB49Q38978839-7A0890E9-9833-4FAA-AB92-1222219059DBQ41167815-A9C8D18F-5227-478E-BC23-1DE2C3EBDAA3Q41552639-718C4D2E-1807-4012-AA1F-1990A6E618D9Q42662678-C1885633-3F3B-43FF-9714-E71D6904D900Q43625600-02D54453-E52E-40FA-8957-B247ABED4AF5Q43703057-E80DEA63-A8F9-4790-AAFE-0B6A38827DA3
P2860
Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@en
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@nl
type
label
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@en
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@nl
prefLabel
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@en
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@nl
P2093
P1476
Serous tubal intraepithelial c ...... clues to serous tumor origin?
@en
P2093
Christopher P Crum
David Kindelberger
Michael H Roh
P304
P356
10.1097/PAS.0B013E3181868904
P407
P577
2009-03-01T00:00:00Z